收藏切换
Research Progress on Bovine-derived Heparin and Low Molecular Weight Heparin Prepared Therefrom
收藏切换
Xi DU1, 2, Fang LAN1, 2, *, Xiaoxiao ZHAO1, Yanli DONG1, Zhimin LI1, 2
Chinese Journal of Pharmaceuticals | 2025, 56(11) : 1379 - 1385
Less
收藏切换
Chinese Journal of Pharmaceuticals | 2025, 56(11): 1379-1385
• Perspectives & Review •
Research Progress on Bovine-derived Heparin and Low Molecular Weight Heparin Prepared Therefrom
Full
Xi DU1, 2, Fang LAN1, 2, *, Xiaoxiao ZHAO1, Yanli DONG1, Zhimin LI1, 2
Affiliations
  • 1.Hebei Changshan Biochemical Pharmaceutical Co., Ltd., Shijiazhuang 050800
  • 2.Hebei Province Polysaccharide Drug Technology Innovation Center, Shijiazhuang 050800
Published: 2025-11-10 doi: 10.16522/j.cnki.cjph.2025.11.002
Outline
收藏切换

Heparin is widely used clinically as an anticoagulant drug, with its main source being porcine intestinal mucosa. Due to the impacts of the heparin sodium incident and the African swine fever incident, a supply shortage of porcine-derived heparin was once caused. Therefore, the FDA encourages manufacturers to increase the supply of heparin from other sources to mitigate the risk associated with relying on a single source. This paper focuses on bovine-derived heparin, analyzing differences from porcine-derived heparin in relative molecular weight, anticoagulant activity, and chemical structure (including monosaccharides, disaccharides, and tetrasaccharides). And the research progress on the preparation of low molecular weight heparin (LMWH) from bovine-derived heparin is also reviewed. Unfractionated bovine heparin can be directly applied to clinical practice, but due to its lower anticoagulant activity, it requires approximately twice the dose of porcine heparin to achieve the same effect. There are significant differences in structure and anticoagulant activity between bovine LMWH and porcine LMWH. Thus, if bovine LMWH is to be developed as a drug, it may need to be registered in accordance with the standards for new drugs.

bovine-derived heparin  /  species source  /  anticoagulant activity  /  chemical structure  /  low molecular weight heparin  /  anticoagulant drug  /  research progress
杜曦, 兰舫, 赵晓晓, 董艳丽, 李志敏. 牛源肝素及其制备的低分子肝素的研究进展. 中国医药工业杂志, 2025 , 56 (11) : 1379 -1385 . DOI: 10.16522/j.cnki.cjph.2025.11.002
Xi DU, Fang LAN, Xiaoxiao ZHAO, Yanli DONG, Zhimin LI. Research Progress on Bovine-derived Heparin and Low Molecular Weight Heparin Prepared Therefrom[J]. Chinese Journal of Pharmaceuticals, 2025 , 56 (11) : 1379 -1385 . DOI: 10.16522/j.cnki.cjph.2025.11.002
Year 2025 volume 56 Issue 11
37
9
Cite this Article
BibTeX
Article Info
doi: 10.16522/j.cnki.cjph.2025.11.002
  • Receive Date:2024-08-30
  • Online Date:2026-11-18
  • Published:2025-11-10
Article Data
Affiliations
History
  • Received:2024-08-30
Funding
Affiliations
    1.Hebei Changshan Biochemical Pharmaceutical Co., Ltd., Shijiazhuang 050800
    2.Hebei Province Polysaccharide Drug Technology Innovation Center, Shijiazhuang 050800
References
Share
https://castjournals.cast.org.cn/joweb/zgyygy/EN/10.16522/j.cnki.cjph.2025.11.002
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT